2023
Nonalcoholic liver disease: Epidemiology, risk factors, natural history, and management strategies
Agyapong G, Dashti F, Banini B. Nonalcoholic liver disease: Epidemiology, risk factors, natural history, and management strategies. Annals Of The New York Academy Of Sciences 2023, 1526: 16-29. PMID: 37400359, PMCID: PMC10524684, DOI: 10.1111/nyas.15012.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNonalcoholic fatty liver diseaseNonalcoholic fatty liverLiver diseaseRisk factorsCommon chronic liver diseaseEnd-stage liver diseaseNatural historyNAFLD risk factorsChronic liver diseaseFatty liver diseaseCurrent management strategiesClinicopathologic spectrumLiver transplantationNonalcoholic steatohepatitisProgressive fibrosisFatty liverHepatocellular cancerLeading indicationDiseaseUnited StatesManagement strategiesCirrhosisSteatohepatitisTransplantationFibrosisNew uses for an old remedy: Digoxin as a potential treatment for steatohepatitis and other disorders
Jamshed F, Dashti F, Ouyang X, Mehal W, Banini B. New uses for an old remedy: Digoxin as a potential treatment for steatohepatitis and other disorders. World Journal Of Gastroenterology 2023, 29: 1824-1837. PMID: 37032732, PMCID: PMC10080697, DOI: 10.3748/wjg.v29.i12.1824.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2020
Knockout of sulfatase 2 is associated with decreased steatohepatitis and fibrosis in a mouse model of nonalcoholic fatty liver disease
Kim TH, Banini BA, Asumda FZ, Campbell NA, Hu C, Moser CD, Shire AM, Han S, Ma C, Krishnan A, Mounajjed T, White TA, Gores GJ, LeBrasseur NK, Charlton MR, Roberts LR. Knockout of sulfatase 2 is associated with decreased steatohepatitis and fibrosis in a mouse model of nonalcoholic fatty liver disease. AJP Gastrointestinal And Liver Physiology 2020, 319: g333-g344. PMID: 32683952, PMCID: PMC7509257, DOI: 10.1152/ajpgi.00150.2019.Peer-Reviewed Original ResearchConceptsFast food dietStandard chow dietWT miceDiet-induced steatohepatitisNonalcoholic steatohepatitisSulfatase 2Hepatic fibrosisMouse modelStandard chow diet ad libitumChow diet ad libitumNonalcoholic fatty liver diseaseDiet-induced mouse modelConditions of overnutritionProtein expressionFatty liver diseasePotential therapeutic mechanismWild-type miceDiet ad libitumThreefold increaseLiver diseaseChow dietKO miceLiver fibrosisSteatohepatitisMurine model